Movers and SHAKERS
Helix Biopharma (HBPCF)(HBP:CA)
Q3 F2020 Earnings: More Value to Add in 2020
As of April 24, 2020, Noble Capital Markets research on Helix Biopharma is published under ticker symbols (HBPCF and HBP:CA). The price target is in USD and based on ticker symbol HBPCF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target. Helix BioPharma Corp is a Canada-based clinical-stage biopharmaceutical company focused on cancer drug development. It develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. The company has Tumor Defense Breakers (L-DOS47), and Tumor Attackers (CAR-T) product candidates in the pipeline.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Q3 F2020 financial results. The company reported the third quarter fiscal year ended April 30, 2020. Net operating loss was $2.5 million for the quarter with $1.5 million research and development expenses and $0.9 million general and administrative expenses. Helix reported ($0.02) EPS.
Updating estimates. We are adjusting our F2020 revenue and operating expense estimates. We have increased our R&D expenses to $6.4 million and reduced SG&A expense estimate to $2.7 million from $2.9 million. We are not expecting any pharma revenue this or next year. Previously we anticipated ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.